Previous studies have demonstrated that the molecular landscape is very different among SF3B1-mutated MDS, MDS/MPN and acute myeloid leukemia patients and that co-mutations contribute to diverse clinical and morphological features [31, 36]. The gene discussed is SF3B1; the disease is myeloproliferative disorder.